Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 261

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 15
Chunk 261
---
$39.6 $26.5 Operating income %9.4 %6.1 %

Net sales decreased $14.8 million, or 3.4%, due primarily to: 

•$21.3 million decrease due to the prior year divestitures of the Rare Diseases and Hospital and Specialty Businesses and the sale of branded products;

•$12.2 million decrease from unfavorable foreign currency translation; partially offset by

•$18.7 million increase, or 4.5%, due primarily to higher net sales of $11.4 million in the Upper Respiratory and Pain and Sleep-Aids categories, due primarily to higher incidence levels of cough cold compared to the prior year period and improved supply of key products, as well as higher net sales of $4.9 million in the Healthy Lifestyle category led by strong momentum in smoking cessation brand NiQuitin®, and $2.7 million from the Skin Care category led by brands Compeed® and Sebamed®, and earlier customer purchases ahead of the spring/summer season compared to the prior year period.

43

Perrigo Company plc - Item 2CSCI

CSCI net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)March 29, 2025March 30, 2024$ Change% ChangeSkin Care$111.5 $114.7 $(3.2)(2.8)%Upper Respiratory73.5 69.1 4.4 6.4 %Healthy Lifestyle66.6 64.6 2.0 3.1 %Pain and Sleep-Aids53.6 51.4 2.2 4.3 %VMS37.7 44.6 (6.9)(15.5)%Women's Health32.4 32.0 0.4 1.3 %Oral Care22.5 28.7 (6.2)(21.6)%Digestive Health9.6 9.5 0.1 1.1 %Other CSCI15.9 23.3 (7.4)(31.8)%Total CSCI$423.1 $437.9 $(14.8)(3.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $111.5 million decreased 2.8%, inclusive of a